The stock of NeoGenomics, Inc. (NASDAQ:NEO) is a huge mover today! About 260,893 shares traded hands or 20.58% up from the average. NeoGenomics, Inc. (NASDAQ:NEO) has risen 19.91% since March 9, 2016 and is uptrending. It has outperformed by 12.50% the S&P500.
The move comes after 5 months negative chart setup for the $595.11 million company. It was reported on Oct, 12 by Barchart.com. We have $7.19 PT which if reached, will make NASDAQ:NEO worth $47.61M less.
Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on November, 3. NEO’s profit will be $761,010 for 195.50 P/E if the $0.01 EPS becomes a reality. After $0.02 actual EPS reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts -50.00% negative EPS growth.
NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage
Out of 7 analysts covering NeoGenomics (NASDAQ:NEO), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. NeoGenomics has been the topic of 9 analyst reports since September 3, 2015 according to StockzIntelligence Inc. On Wednesday, May 11 the stock rating was reinitiated by Roth Capital with “Buy”. The rating was downgraded by BTIG Research to “Neutral” on Wednesday, July 27. Benchmark initiated NeoGenomics, Inc. (NASDAQ:NEO) on Friday, March 11 with “Buy” rating. First Analysis initiated NeoGenomics, Inc. (NASDAQ:NEO) rating on Tuesday, October 4. First Analysis has “Overweight” rating and $11 price target. As per Monday, October 26, the company rating was reinitiated by TH Capital. The rating was maintained by William Blair with “Outperform” on Sunday, September 6. The company was maintained on Thursday, September 3 by Roth Capital.
According to Zacks Investment Research, “NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.”
Insitutional Activity: The institutional sentiment increased to 2 in 2016 Q2. Its up 0.78, from 1.22 in 2016Q1. The ratio is positive, as 5 funds sold all NeoGenomics, Inc. shares owned while 34 reduced positions. 36 funds bought stakes while 42 increased positions. They now own 57.99 million shares or 3.94% more from 55.79 million shares in 2016Q1.
Gamco Investors Inc Et Al last reported 50,000 shares in the company. The Illinois-based Bard Associate has invested 1.26% in NeoGenomics, Inc. (NASDAQ:NEO). Brick & Kyle Associate reported 9,000 shares or 0.06% of all its holdings. Terril Brothers Inc accumulated 52,500 shares or 0.19% of the stock. Moreover, Commonwealth Svcs Limited Liability Company has 0.02% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 2,000 shares. Tower Research Ltd Liability Co (Trc) holds 3,492 shares or 0% of its portfolio. Tfs Cap Ltd Limited Liability Company has 0.13% invested in the company for 89,892 shares. Analytic Investors Ltd Limited Liability Company has invested 0.01% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Swiss National Bank & Trust last reported 0% of its portfolio in the stock. The Minnesota-based Perkins Capital Mngmt Incorporated has invested 6.2% in NeoGenomics, Inc. (NASDAQ:NEO). Credit Suisse Ag last reported 121,896 shares in the company. Deere last reported 0.01% of its portfolio in the stock. The Illinois-based Rmb Management Ltd Limited Liability Company has invested 0.86% in NeoGenomics, Inc. (NASDAQ:NEO). Rhumbline Advisers accumulated 51,535 shares or 0% of the stock. White Pine Capital holds 100,625 shares or 0.34% of its portfolio.
Insider Transactions: Since April 20, 2016, the stock had 0 buys, and 9 sales for $11.28 million net activity. ROSS STEVEN A also sold $123,300 worth of NeoGenomics, Inc. (NASDAQ:NEO) on Monday, May 9. Shares for $3.05M were sold by ALBITAR MAHER on Friday, August 19. Another trade for 177,745 shares valued at $1.46M was made by JONES STEVEN C on Wednesday, April 20. $4.20 million worth of shares were sold by VAN OORT DOUGLAS M on Wednesday, May 25.
More notable recent NeoGenomics, Inc. (NASDAQ:NEO) news were published by: Fool.com which released: “Why Neogenomics Inc is Soaring Higher Today” on October 21, 2015, also Prnewswire.com with their article: “NeoGenomics Completes Acquisition of Clarient, Inc.” published on December 30, 2015, Quotes.Wsj.com published: “NeoGenomics Inc. NEO (US: Nasdaq)” on May 30, 2011. More interesting news about NeoGenomics, Inc. (NASDAQ:NEO) were released by: Twst.com and their article: “NeoGenomics Inc.: NeoGenomics Schedules its Q3 2016 Earnings Release for …” published on October 11, 2016 as well as Prnewswire.com‘s news article titled: “NeoGenomics signs Definitive Agreement to acquire Clarient, Inc.” with publication date: October 21, 2015.
NEO Company Profile
NeoGenomics, Inc., incorporated on October 28, 1998, is an operator of a network of cancer-focused genetic testing laboratories. The Firm operates in Laboratory Testing Segment. The Company’s Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Firm has laboratory locations in Ft. Myers and Tampa, Florida; Fresno, Irvine, and West Sacramento, California, and Nashville, Tennessee. The Firm offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues; molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level; Pathology consultation- services provided for clients in which the Company’s pathologists review surgical samples on a consultative basis, and Pharma Services and Clinical Trials-Services supporting pharmaceutical firms in their drug development programs by supporting various clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.